Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa

Haemophilia

Volumn 16, Issue 2, 2010, Pages 290-295

  Takedani, H ^a   Kawahara, H ^b   Kajiwara, M ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b National Hospital Organization Tsuruga Medical Center   (Japan)

Author keywords

Inhibitor; Orthopaedic surgery; RFVIIa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ADOLESCENT; ADULT; ARTHROPLASTY; ARTHROSCOPIC SURGERY; ARTICLE; BLEEDING; BOLUS INJECTION; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SCHOOL CHILD; SYNOVECTOMY;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD LOSS, SURGICAL; CHILD; FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; MIDDLE AGED; MUSCULOSKELETAL DISEASES; RECOMBINANT PROTEINS;

EID: 77950207190     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02149.x     Document Type: Article

References (25)

1. Rodriguez-Merchan EC, Quintana M, Jimenez-Yuste V, Hernandez-Navarro F. Orthopaedic surgery for inhibitor patients: a series of 27 procedures (25 patients). Haemophilia 2007, 13:613-9.
2. Jimenez-Yuste V, Rodriguez-Merchan EC, Alvarez MT, Quintana M, Fernandez I, Hernandez-Navarro F. Controversies and challenges in elective orthopedic surgery in patients with hemophilia and inhibitors. Semin Hematol 2008, 45:S64-7.
3. Morfini M, Haya S, Tagariello G. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007, 13:606-12.
4. Obergfell A, Auvinen MK, Mathew P. Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature. Haemophilia 2008, 14:233-41.
5. Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007, 98:726-32.
6. Teitel JM, Carcao M, Lillicrap D. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009, 15:227-39.
7. Hedner U, Glazer S, Pingel K. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988, 2:1193.
8. Habermann B, Hochmuth K, Hovy L, Scharrer I, Kurth AH. Management of haemophilic patients with inhibitors in major orthopaedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven): a single centre experience. Haemophilia 2004, 10:705-12.
9. Rodriguez-Merchan EC, Wiedel JD, Wallny T. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003, 9:625-31.
10. Solimeno LP, Perfetto OS, Pasta G, Santagostino E. Total joint replacement in patients with inhibitors. Haemophilia 2006, 12(Suppl. 3):113-16.
11. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001, 85:958-65.
12. Pan-Petesch B, Laguna P, Mital A. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres. Haemophilia 2009, 15:760-5.
13. Salaj P, Brabec P, Penka M. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009, 15:752-9.
14. Giangrande PL, Wilde JT, Madan B. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 2009, 15:501-8.
15. Schulman S. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness. Semin Thromb Hemost 2000, 26:421-4.
16. Schulman S, Bech Jensen M, Varon D. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996, 75:432-6.
17. Schulman S, Varon D, Keller N, Gitel S, Martinowitz U. Monoclonal purified FVIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost 1994, 72:403-7.
18. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003, 120:808-13.
19. Mauser-Bunschoten EP, de Goede-Bolder A, Wielenga JJ, Levi M, Peerlinck K. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in the Netherlands and Belgium. Neth J Med 1998, 53:249-55.
20. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001, 86:954-8.
21. Lorenzo JI, Montoro JM, Aznar JA. Postoperative use of rFVIIa by continuous infusion in a haemophilic boy. Haemophilia 1999, 5:135-8.
22. Perez R, Martinez RL, Pinero A, Sosa R. Sequential treatment with bolus and continuous infusion of recombinant factor VIIa for hip arthroplasty in a patient with haemophilia A and inhibitor. Haemophilia 2002, 8:822-5.
23. Tagariello G, Bisson R, Radossi P. Concurrent total hip and knee replacements in a patient with haemophilia with inhibitors using recombinant factor VIIa by continuous infusion. Haemophilia 2003, 9:738-40.
24. Tagariello G, De Biasi E, Gajo GB. Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases. Haemophilia 2000, 6:581-3.
25. Smith MP, Ludlam CA, Collins PW. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 2001, 86:949-53.